Physician profile
Hugo Hool
NPI 1417944489
$1,610.68
in general payments reported to CMS, 2019-2025
33 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.95 · 2021: $56.77 · 2022: $78.41 · 2023: $575 · 2024: $491 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.55 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $505.02 | 2022-2025 | Calquence |
| Genentech USA, INC. | $126.51 | 2022-2025 | Tecentriq, Venclexta |
| Pfizer INC. | $107.79 | 2023-2024 | |
| Celgene Corporation | $105.51 | 2022-2025 | Reblozyl |
| Array Biopharma INC | $80.55 | 2024-2025 | Tukysa, Braftovi, Mektovi |
| Eisai INC. | $80.10 | 2024 | |
| Puma Biotechnology, INC. | $65.38 | 2025 | |
| Merck Sharp & Dohme LLC | $51.11 | 2022-2025 | Keytruda, Welireg |
| Kite Pharma, INC. | $50.51 | 2023 | |
| Abbvie INC. | $48.41 | 2023-2024 | |
| Glaxosmithkline, LLC. | $43.37 | 2023-2024 | Jemperli, Zejula |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Janssen Biotech, INC. | $38.36 | 2023-2025 | Erleada, Balversa |
| Emd Serono, INC. | $29.56 | 2024 | |
| Daiichi Sankyo INC. | $27.76 | 2023 | Enhertu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.48 | 2020 | |
| Jazz Pharmaceuticals INC. | $23.12 | 2023 | |
| Spectrum Pharmaceuticals INC. | $21.83 | 2024 | Rolvedon |
| Stemline Therapeutics INC. | $20.84 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $20.82 | 2024 | |
| Seagen INC. | $20.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | |
| Acrotech Biopharma INC. | $16.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.38 | 2021 | |
| Beigene USA, INC. | $13.25 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Hool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.